AstraZeneca acquires Omniose to add single‑cell bioconjugation vaccine platform
AstraZeneca has completed the acquisition of Omniose, a pre‑clinical biotech that developed a single‑cell bioconjugation platform for polysaccharide‑conjugate vaccines. The deal follows a three‑year exclusive research collaboration and makes Omniose a wholly‑owned subsidiary of AstraZeneca’s Infectious Disease Unit. Financial terms were not disclosed and AstraZeneca shares fell about 1.5% after the announcement.
Why it matters
The company says the technology will strengthen its vaccine research and may simplify manufacturing of bacterial vaccines, potentially expanding its pipeline against antimicrobial‑resistant infections. The acquisition does not immediately affect cash flow but adds a new capability to AstraZeneca’s infectious‑disease portfolio.
Key facts
- 1AstraZeneca acquired Omniose, a pre‑clinical biotechnology company developing polysaccharide conjugate vaccines. rttnews.com
- 2The acquisition follows a three‑year exclusive research collaboration between the two companies. rttnews.com
- 3Omniose’s platform links bacterial polysaccharides to carrier proteins within a single cell using a conjugating enzyme. rttnews.com
- 4Omniose becomes a wholly‑owned subsidiary of AstraZeneca and will be integrated into its Infectious Disease Unit. rttnews.com
- 5Financial terms of the acquisition were not disclosed. rttnews.com
- 6AstraZeneca shares were down 1.50% to $186.48 after the announcement. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.